Skip to main content

Table 1 Clinical activity of targeted therapies for treatment of recurrent ovarian cancer in heavily pretreated patients

From: Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

  Phase Patients with OC, n Previous therapies ORR, n (%) CR, n (%) Median DoR, mo Median PFS, mo OS, mo
Bevacizumab Monotherapy
 Cannistra 2007 [21] 2 44 2–3 7 (16) 0 4.2 4.4 10.7
 Burger 2007 [22] 2 62 1–2 13 (21) 2 (3) 10.3 4.7 16.9
 Monk 2006 [23]   32 5 (range: 2–10) 5 (16) 1 (3) NR 5.5 6.9
 Pietzner 2011 [24]   15 5.4 (range: 1–7) 2 (13) 0 NR NR 15.0
Bevacizumab-Chemotherapy Combination
 AURELIA [25] 3 361 ≤2 27.3% NR NR 6.7 16.6
 OCEANS [26, 27] 2 484 ≤1 190/242 (78.5) 42 (17) 10.4 12.4 33.6
 GOG-213 [28] 3 674 ≥3 196/249 (78) 79/249 (32) NR 13.8 42.2
Olaparib Monotherapy
 Kaufman 2015 [29] 2 193 4.3 ± 2.2 (SD) 60 (31) 6 (3) 7.5 7 16.6
  ≥ 3 Prior lines [30]a   137a ≥3 46 (34) 2 (2) 7.9 6.7 NR
 Gelmon 2011 [31] 2 65 3 (range: 1–10) 18 (29) 0 NR 7.3 NR
Rucaparib Monotherapy
 Swisher 2017 [32] 2        
   BRCA mutant   40 1–2 32 (80) NR 9.2 12.8 NR
   BRCA wild-type
   LOH high   82 1–2 24 (29) NR 10.8 5.7 NR
   LOH low   70 1–2 7 (10)   5.6 5.2  
  1. CR complete response, DoR duration of response, LOH loss-of-heterozygosity score, mo months, NR not reported, OC ovarian cancer, ORR objective/overall response rate, OS overall survival, PFS progression-free survival, SD standard deviation
  2. aSubset of patients in Kaufman/Domchek who had measurable disease at baseline and ≥3 prior lines of chemotherapy